Microbot Medical Inc. 8-K

What Happened

• On June 16, 2026 Microbot Medical Inc. announced (via an 8‑K Regulation FD disclosure) that it entered a vendor agreement with Lovell Government Services. The agreement "creates an opportunity to sell" the company’s LIBERTY® Endovascular Robotic System at more than 2,000 U.S. government facilities. The company furnished a press release describing the agreement as Exhibit 99.1 to the Form 8‑K.

Key Details

• Announcement date: June 16, 2026 (filed on Form 8‑K, Item 7.01).
• Partner: Lovell Government Services (vendor agreement).
• Product: LIBERTY® Endovascular Robotic System.
• Opportunity coverage: more than 2,000 U.S. government facilities.
• No financial terms, revenue estimates, or delivery/timing details were disclosed in the filing.

Why It Matters

• For investors, the agreement may expand Microbot’s potential sales channels into the U.S. government market and increase its addressable customer base; however, the filing does not disclose guaranteed purchases, pricing, timelines, or expected revenue impact. This is a business-development milestone but not a confirmation of sales or financial guidance.